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Atopic dermatitis is a common skin disease of un-
known etiology with an impaired permeability bar-
rier function. To learn more about the molecular
pathology in lesional skin, we analyzed levels of free
extractable as well as protein-bound barrier lipids in
the epidermis of atopic dermatitis subjects. The
amount of protein-bound w-hydroxyceramides in
healthy epidermis comprised 46±53 wt% of total
protein-bound lipids, whereas this percentage was
decreased to 23±28 wt% in nonlesional areas and
even down to 10±25 wt% in affected atopic skin
areas of the subjects. Furthermore, the partial
amount of free extractable very long chain fatty
acids with more than 24 carbon atoms was reduced
in affected regions down to 25 wt% and in non-
lesional regions of the atopic dermatitis subjects
down to 40 wt% compared to healthy controls. This
``hydrocarbon chain length de®ciency'' regarding the
barrier lipids in atopic skin was supported by meta-
bolic labeling studies with [14C]-serine in cultured
epidermis. The biosynthesis of free glucosylcera-
mides and free ceramides was remarkably decreased
in affected skin areas of the atopic subjects compared
to healthy control subjects. Especially affected were
the de novo syntheses of ceramide 4 (i.e., ceramide
EOH, consisting of a very long chain N-acyl
w-hydroxy fatty acid esteri®ed with linoleic acid and
6-hydroxysphingosine as sphingoid base) and cera-
mide 3 (ceramide NP, consisting of a nonhydroxy
N-acyl fatty acid and phytosphingosine). In conclu-
sion, this study revealed that the lesional epidermis
in atopic dermatitis has considerable de®ciencies
within main barrier lipid components, which may
contribute to the severely damaged permeability bar-
rier. Key words: atopic skin/covalently bound lipids/epi-
dermal permeability barrier/sphingolipids/very long chain
fatty acids. J Invest Dermatol 119:166±173, 2002
A
topic dermatitis (AD) appears to be an increasing
medical problem nowadays (Hermann-Kunz, 2000;
Foley et al, 2001). Most of the atopic subjects possess a
genetic predisposition for this in¯ammatory skin
disease, which is presumably triggered by an allergic
overreaction of the immune system (Wollenberg and Bieber,
2000). The lesional skin appears rather dry as a consequence of an
impaired permeability barrier function, which ¯uctuates with
disease activity. This reduced barrier function seems to be a
consequence of inadequate structural and metabolic conditions
within the epidermis (Jensen et al, 2000).
The permeability barrier is located in the stratum corneum, the
outermost epidermal layer, which consists of a densely packed
system of corneocytes embedded in an intercellular multilamellar
lipid matrix. The lipid composition in the stratum corneum varies
interindividually (NorleÂn et al, 1999) as well as with the age
(Ghadially et al, 1995) and the season (Rogers et al, 1996).
Nevertheless, abnormal patient pro®les are discernible and associ-
ated with de®cient barrier function in different atopic skin sites
(Melnik et al, 1990). The total lipid amount in the stratum corneum
of atopic affected skin, as analyzed after single cyanoacrylate tape
stripping, seems to be reduced to about 50% compared to healthy
controls (Imokawa et al, 1991). Most of these intercorneocyte
barrier lipids, predominantly ceramides together with cholesterol
and free fatty acids (FFA), are unbound and thus free extractable
with organic solvents (Lampe et al, 1983; NorleÂn et al, 1998;
Vietzke et al, 2001).
Free extractable ceramides are the best investigated lipid species in
AD epidermis, as they represent the main lipid component of the
permeability barrier. Although the results vary in the different
examinations with regard to the diversity of sampling techniques, it
seems that the total ceramide amount in AD affected skin is
signi®cantly reduced (Melnik et al, 1988; Imokawa et al, 1991;
Yamamoto et al, 1991; Di Nardo et al, 1998; Matsumoto et al, 1998).
There is a precursor±product relationship between unique
epidermal fatty acids and ceramides (Monger et al, 1988; Behne
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et al, 2000). The metabolically active layers of the epidermis are able
to produce very long chain fatty acids (VLCFA), the biosynthesis of
which still remains unclear. It was reported that the content of an
FFA fraction with 20±26 carbon atoms is decreased in AD (SchaÈfer
and Kragballe, 1991).
The content of cholesterol in AD is slightly increased (Di Nardo
et al, 1998), and the amount of phospholipids is nearly twice as high
as in healthy epidermis (SchaÈfer and Kragballe, 1991). The partial
amounts of other stratum corneum lipid classes including choles-
terol esters and cholesterol sulfate were investigated after washing
the ¯exural region of the forearm with 95% ethanol, but did not
differ statistically between AD patients and normal controls
(Yamamoto et al, 1991).
An important role in epidermal barrier homeostasis has also been
attributed to glucosylceramides, which are more rare in the stratum
corneum, but they represent the main physiologic precursors of
barrier ceramides (Holleran et al, 1993). Although the molecular
details concerning their biogenesis during epidermal differentiation
are not known, glucosylceramides occur in lamellar bodies
(Freinkel and Traczyk, 1985; Grayson et al, 1985), speci®c
organelles in the upper living layers of the epidermis, which
secrete their contents into the intercellular space of the stratum
corneum (Fartasch and Diepgen, 1992).
The human epidermis also contains covalently bound ceramides
and fatty acids (Wertz and Downing, 1986). They can be analyzed
after exhaustive extraction of the free epidermal lipids and the
release through mild alkaline hydrolysis (Wertz and Downing,
1987; Wertz et al, 1989). Recently, we detected protein-bound
w-hydroxyglucosylceramides in mouse epidermis as possible pre-
cursors of the protein-bound w-hydroxyceramides (w-OH-Cer),
which are subsequently degraded to protein-bound w-hydroxy
fatty acids (w-OH-FA) (Doering et al, 1999a; 1999b).
The w-OH-Cer are attached by ester linkage of their w-hydroxy
group mainly to involucrin, a structural protein of the epidermal
corni®ed envelope (Marekov and Steinert, 1998; Doering et al,
1999a; 1999b; Nemes et al, 1999; Stewart and Downing, 2001).
They are assumed, together with w-OH-FA, to form a lipid
monolayer that surrounds the corneocyte and seem to be of great
relevance concerning the barrier function of the epidermis
(Meguro et al, 2000).
In order to examine the relationship between abnormalities of
the protein-bound epidermal lipid ratios and atopic dry skin, we
investigated whether these important barrier lipids are affected in
the epidermis of subjects with AD. We also provide more detailed
data about the free extractable epidermal lipids in AD, analyze the
composition of free VLCFA with more than 24 carbon atoms, and
determine the capacity of AD affected epidermis to produce the
free extractable glucosylceramides and ceramides as the major
epidermal lipids.
MATERIALS AND METHODS
Subject and sample collection The epidermis of 10 AD subjects
(nine male, one female) ranging in age from 14 to 45 y with acute AD
was investigated. Informed consent was obtained from all volunteers
participating in the study. If not indicated otherwise, the investigated
skin was disinfected with betaisodonna solution (Mundipharma, Limburg,
Germany) and washed with sterile isotonic 0.9% saline solution (Braun
Melsungen, Melsungen, Germany); a shave-biopsy from the forearm was
used for lipid analysis. As far as available (eight subjects) we compared
affected with nonlesional skin of the same subject. The subjects had no
topical treatment during the week before the investigation. All subjects
were diagnosed according to Hani®n and Rajka (1980). Samples of
healthy control skin were taken from the forearm and on the occasion of
surgical operations (foreskin, abdomen, and breast) with volunteers'
approval.
Chemicals and reagents Dispase solution (grade II, > 2.4 units per
ml, Roche Molecular Biochemicals, Mannheim, Germany) and Hank's
balanced salt solution (HBSS; Gibco BRL, Life Technologies, Paisley,
U.K.) were used for epidermis preparation. Metabolic labeling with
L-[3-14C]-serine (54 Ci per mol, Amersham Pharmacia Biotech,
Freiburg, Germany) was performed in MCDB 153 medium (Biochrom,
Berlin, Germany) supplemented with 1.1 mM Ca2+ and 10 mM linoleic
acid. Liquid scintillation counting was carried out with Ultima GOLD
scintillation cocktail (Packard Instruments, Groningen, The Netherlands).
Methanol, chloroform, LiChroprep RP-18, thin-layer chromatography
(TLC) plates (20 3 20 cm, Silica Gel 60), orthophosphoric acid (85%),
and copper (II) sulfate pentahydrate were purchased from Merck eurolab
(Darmstadt, Germany). Anionic lipids were separated by DEAE-
Sephadex A-25 anion exchanger (Pharmacia Biotech, Uppsala, Sweden).
Hexacosanoic acid (C26 : 0), octacosanoic acid (C28 : 0), and
triacontanoic acid (C30 : 0), for the syntheses of VLCFA methyl ester
reference standards, and oil reference standard AOCS no. 3 for gas
chromatography were obtained from Sigma (Deisenhofen, Germany).
The FFA methyl esters were synthesized with diazomethane, which was
freshly distilled from Diazald (Aldrich, Taufkirchen, Germany) as starting
material (Leonhard et al, 1996).
Preparation of epidermis The shave-biopsies (1±4 cm2) were laid
with the dermis side downwards on a one to one (vol/vol) mixture of
Dispase solution and HBSS overnight at 4°C, and afterwards the
epidermis was separated from dermal components. In metabolic labeling
studies, we compared the determined wet weights. For all other studies
the epidermis was homogenized in water with a Potter homogenizer and
lyophilized overnight to determine the dry weight.
Extraction of free lipids The lipids from homogenized and
lyophilized tissue were sequentially extracted with different solvent
mixtures at 37°C for at least 6 h: chloroform/methanol/water (1:2:0.6,
vol/vol/vol) (modi®ed according to Bligh and Dyer, 1959), chloroform/
methanol (1:1, vol/vol), and chloroform/methanol (2:1, vol/vol). For
desalting, the lipid extracts were evaporated to dryness, dissolved in 1 ml
methanol, and applied to a LiChroprep RP-18 column, prewashed with
water, methanol, and chloroform/methanol (1:1, vol/vol). The salts were
removed with 6 ml water and the lipids were eluted with 8 ml
chloroform/methanol (1:1, vol/vol). Separation of negatively charged
FFA was carried out with a Sephadex A-25 anion exchanger column,
which was prewashed with methanol. The desalted and constricted lipid
solution was applied to the column and the neutral lipids were removed
with 6 ml chloroform/methanol/water (3:7:1, vol/vol/vol). Afterwards,
the anionic lipids were eluted with 6 ml chloroform/methanol/0.8 M
ammoniun acetate solution (3:7:1, vol/vol/vol).
Release of covalently bound lipids The homogenized and lyophil-
ized material was extracted with organic solvents as described above. The
remaining pellets were extracted twice with methanol at 37°C for 2 h
and ®nally with methanol/water (95:5, vol/vol) at 60°C for 2 h, until no
free extractable lipids were detectable. This remaining material was
subjected to a mild alkaline hydrolysis to release covalently ester-bound
lipids (1 M potassium hydroxide in 95% methanol, 2 h at 60°C)
(Doering et al, 1999a). The solution was neutralized with acetic acid and
desalted with LiChroprep RP-18.
Lipid analysis The lipid samples were applied in lanes to TLC plates,
which were developed twice with chloroform/methanol/acetic acid
(190:9:1, vol/vol/vol) in solvent saturated developing chambers (Desaga,
Heidelberg, Germany). TLC plates were sprayed with an aqueous
solution of 10% (by weight) copper (II) sulfate pentahydrate and 8% (by
weight) orthophosphoric acid (85%) (Imokawa et al, 1991), charred at
180°C for 8 min, and quanti®ed by scanning densitometry at 595 nm
(Shimadzu CS 9301 PC, Kyoto, Japan). Lipids were identi®ed by
comparing their mobilities with commercially available and authentic
reference standards previously analyzed by MALDI mass spectrometry
(micromass TofSpecE, Manchester, U.K.) (Doering et al, 1999a).
Metabolic labeling studies The freshly prepared epidermis was ¯oated
dermis side downwards on MCDB 153 medium, supplemented with
calcium chloride (1.1 mM) and linoleic acid (10 mM). L-[3-14C]-serine
was added to a ®nal concentration of 1 mCi per ml medium. The
epidermis was incubated in a 35 mm plastic cell culture dish for 24 h at
37°C in 5% CO2 atmosphere. Afterwards, the epidermis was minced and
lipid analysis was carried out as described above. The incorporated
radioactivity was quanti®ed with a liquid scintillation counter (Packard
Instruments and Tri-Carb 1900 CA, Connecticut), and visualized after
TLC separation by phospho-imager analysis (FUJIX BAS1000, Fuji
Photo Film, Tokyo, Japan).
Fatty acid analysis The isolated fatty acids (anionic fraction of free
extractable lipids) were methylated with freshly distilled diazomethane
(Leonhard et al, 1996). The fatty acid methyl esters were analyzed by
capillary gas chromatography using a Hewlett Packard 5890 (series II)
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apparatus with an HP-1 capillary column (polydimethylsiloxane, 25 m 3
0.20 mm, ®lm thickness 0.33 mm; Hewlett Packard, Palo Alto, CA) and
nitrogen as carrier gas. The following conditions were worked out for
the temperature program: start with 4 min at 150°C, then heating up to
250°C at 4°C per min, and maintaining at 250°C for 10 min. The FFA
methyl esters were detected by ¯ame ionization detection and identi®ed
by comparing their retention times with those of commercially available
or self-synthesized reference standards.
RESULTS
Protein-bound lipids in atopic epidermis Protein-bound
lipids are considered to play an essential role in epidermal barrier
function. This became even more evident after our discovery of
protein-bound glucosylceramides and their disturbed metabolism in
mouse models of sphingolipid storage diseases (Doering et al, 1999a;
1999b). Therefore, we investigated protein-bound lipid species in
AD subjects. A comparison between healthy controls on the one
hand and affected as well as nonlesional skin areas of the same atopic
subject on the other hand revealed a correlation between reduced
amounts of protein-bound w-OH-Cer and lesional skin in AD
(Fig 1). Quanti®cation of covalently bound lipids released from
epidermis by alkaline hydrolysis, after extraction of unbound lipids,
showed that the amount of protein-bound w-OH-Cer decreased
from about 50 wt% (range 46%±53%) of total bound lipids in
healthy subjects to 25 wt% (range 23%±28%) in the nonlesional area
and down to 15 wt% (range 10%±25%) in the affected area of the
AD subject. This indicates that the de®ciency of protein-bound
w-OH-Cer impairs the permeability barrier in AD.
The function of protein-bound w-OH-Cer in the stratum
corneum could apparently not be accomplished by w-OH-FA.
Their amount in the affected skin areas of subjects with AD is about
50 wt% (range 44%±55%), compared to 42 wt% (range 36%±48%)
Figure 1. Covalently bound lipids in healthy
and atopic human epidermis. Epidermis from
skin biopsies was prepared and analyzed as
described in Materials and Methods. Panel A: ester-
linked lipids were released by mild alkaline
hydrolysis and analyzed by TLC. The
chromatographic separation shows subject with
AD (lesional area and nonlesional area) and
healthy control subject (? = not identi®ed band,
also to be found in lipid extracts from subjects
with AD if more material was applied on the
TLC lane). *Note that complete extracts of
protein-bound lipids from different amounts of
prepared epidermis were applied on each lane (by
dry weights: lesional area 1.7 mg, nonlesional area
2.0 mg, and healthy subject 12.2 mg). Panel B:
densitometric quanti®cation of covalently bound
lipids. Total amounts of protein-bound lipids are
given as the range of lowest to highest values
determined. The composition of protein-bound
lipids is expressed as weight percentage of total
protein-bound lipids; data are presented as the
mean [n is the number of analyzed subjects;
lesional area n = 3 (forearm), nonlesional area n =
3 (forearm), healthy subject n = 5 (forearm (2),
foreskin, breast, abdomen)]. Bars indicate the
range of highest and lowest value measured. The
absolute amounts of individual lipids can be
calculated from the data presented, e.g., the
absolute amounts of w-OH-Cer in mg per mg
epidermal dry weight range as follows: healthy
skin 0.25±2.0, unaffected atopic skin 0.3±1.4, and
affected atopic skin 0.1±1.1.
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in nonlesional areas, and to 25 wt% (range 21%±32%) in healthy
controls. These values refer to the total weight of protein-bound
lipids in each distinct investigated skin sample. The weight
percentage of protein-bound w-OH-FA is increased in affected
skin regions, whereas the weight percentage of protein-bound
w-OH-Cer is decreased, indicating a metabolic relationship
between these two lipoproteins.
We found no signi®cant differences between the investigated
skin biopsies (affected and nonlesional atopic areas as well as healthy
controls) concerning the weight percentage of unhydroxylated fatty
acids, though their content ¯uctuates between different skin
samples, even of the same proband. The combined mass of all
protein-bound lipid species together (w-OH-Cer + w-OH-
FA + FA) per mg dry weight was about in the same range for all
skin samples analyzed: affected atopic, unaffected atopic, and
healthy skin irrespective of the area (forearm, foreskin, abdomen, or
breast).
Free VLCFA in atopic epidermis The pattern of FFA in the
epidermis seems to be important for the capacity of the
permeability barrier function (SchaÈfer and Kragballe, 1991). We
analyzed the less investigated free VLCFA (with more than 24
carbon atoms), and also a fraction of short chain fatty acids (with
less than 16 carbon atoms) in the skin of two healthy subjects and
®ve subjects with AD (Table I). Furthermore, we analyzed the
predominant palmitic acid (C16 : 0) and stearic acid (C18 : 0).
Other components of the fatty acid fraction with 16±24 carbon
atoms showed considerable individual ¯uctuations and are therefore
not presented.
Based on the total mass of whole FFA fractions, the weight
percentage of free VLCFA (with more than 24 carbon atoms) was
reduced at the affected skin sites of subjects with AD to about 25%
of the amount determined in healthy control samples. Nonlesional
skin sites of the same AD subjects also dropped down to 40%
compared to healthy controls. The three predominant species in
this fraction are the saturated VLCFA C26 : 0, C28 : 0, and C30 :
0 (Fig 2). On the other hand the amounts of stearic acid, palmitic
acid, and the short chain fatty acid fraction (with less than 16 carbon
atoms) did not differ noticeably between the affected and the
nonlesional skin sites of atopic subjects and the healthy controls.
Biosynthesis of free epidermal glucosylceramides and
ceramides In comparison to cultured keratinocytes from age-
matched healthy skin shave-biopsies, the proliferation of AD
keratinocytes from shave-biopsies was rather low. Therefore, we
used complete and intact lesional atopic and healthy control
epidermis, which was separated from dermal components by
dispase treatment, for metabolic labeling studies. The epidermal
sheets were ¯oated on MCDB 153 medium, which contained
[3-14C]-serine as a precursor of ceramide and glucosylceramide
biosyntheses.
Although the investigated affected atopic epidermis was able to
produce all speci®c free barrier ceramides within 24 h, the amounts
of newly synthesized free ceramides during this period were
strongly reduced (Fig 3). A comparable sheet of healthy epidermis
incorporated three to four times more radioactive serine into the
sphingolipid fraction than the preparations of subjects affected with
AD. We calculated the amount of material newly synthesized in
24 h and analyzed the relative composition of the total incorporated
radioactivity in glucosylceramides and the ceramide fractions
(Table II).
Compared to healthy controls, the [14C]-serine incorporation in
the total ceramide fraction of the affected skin of atopic subjects
(the nonlesional skin areas were not available) was decreased to 46%
and in the glucosylceramide fraction down to 23%. Also [14C]-
serine incorporation into sphingomyelins was reduced to 45%±50%
at the atopic affected skin sites compared to normal skin (not
shown).
Especially decreased was the labeling of very long chain ceramide
EOH (ceramide 4) and of phytosphingosine-containing ceramide
NP (ceramide 3). On the other hand, labeling of the short chain
ceramide NS (ceramide 2, containing predominantly palmitic acid
and stearic acid; Wertz et al, 1985; Bleck et al, 1999) was only
slightly reduced. Expressed as a percentage of the total free
ceramide fraction, it was even increased from 19% in the healthy
controls to 29% in affected areas of AD subjects (Table II). These
results suggest a de®ciency in the biosynthesis of VLCFA in atopic
affected skin, which was noticeable as well in the fraction of FFA, as
in ceramides or glucosylceramides, that contains VLCFA in amide-
linked form. Taken together, the amount of very long chain barrier
lipids in affected atopic areas is decreased, whereas the relative
amounts of lipids with shorter chain lengths are increased.
Biosynthesis of protein-bound lipids Lesional atopic skin
samples big enough to study the biosynthesis of protein-bound
lipids were obtained only from one volunteer with AD; nonlesional
skin samples of this subject were not available. Therefore, only
preliminary experiments could be performed.
The labeling of the total fraction of protein-bound lipids by
[14C]-serine in 24 h decreased at the affected AD skin sites to about
7.5% of normal healthy control values. Besides this, the partial
amounts of incorporated radioactivity revealed a change in the
proportion of newly synthesized protein-bound lipids. Especially
reduced were the w-hydroxylated lipids w-OH-Cer and w-OH-
FA, as the labeling of both dropped to about 5%, whereas the
Table I. Free extractable epidermal fatty acidsa
Subjects with AD (n = 5)
Healthy subjects (n = 2)Lesional area Non-lesional area
Calculated range of total FFA amounts
(mg per mg epidermal dry weight)b 1±5 1±5 1±5
Weight percentages of the total FFA fractionc
Short chain fatty acids
(less than 16 carbon atoms)
7.7 (6 1.3) 7.6 (6 1.1) 5.4 (6 0.1)
Palmitic acid (C16 : 0) 8.8 (6 2.5) 7.7 (6 2.2) 11.3 (6 0.7)
Stearic acid (C18 : 0) 9.2 (6 2.2) 7.8 (6 2.0) 11.1 (6 0.8)
VLFCA
(more than 24 carbon atoms)
3.7 (6 1.4) 6.1 (6 1.8) 15.7 (6 1.3)
aSkin samples from ®ve subjects with AD and two healthy controls were analyzed. Fatty acids were extracted, prepared, and separated as described in Materials and
Methods. Given are the mean weight percentages (6SEM) of the total free extractable fatty acid fraction.
bThe total amounts of FFA in the epidermis were calculated by gas chromatography peak areas for all atopic subjects (lesional and nonlesional area) and healthy controls.
cThe fatty acid fraction with 16±24 carbon atoms (except palmitic acid and stearic acid) amounts to 50%±80% of the total FFA pool by weight in all healthy and AD sam-
ples analyzed. The fatty acid composition of this fraction varies from individual to individual (data not shown).
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labeling of newly synthesized unhydroxylated fatty acids decreased
only to 15% of their respective normal control values (data not
shown).
DISCUSSION
Covalently bound lipids are attached to the corni®ed envelope of
the corneocytes and are assumed to surround the corneocyte with a
lipid monolayer (Marekov and Steinert, 1998). This lipid species is
thought to play a crucial role in barrier formation (Meguro et al,
2000; Steinert, 2000). The protein-bound barrier lipids have not
been investigated in AD, however. Therefore, we analyzed their
contents in affected and nonlesional skin areas of the same AD
subject, and compared them to those of healthy control subjects.
Though the total amount of protein-bound lipids appeared to be
unchanged, the compositional analysis revealed distinct differences
between the investigated skin areas. The amount of protein-bound
w-OH-Cer was signi®cantly reduced not only at the affected sites
but also at the nonlesional sites of atopic epidermis, compared to
healthy controls. This decrease is accompanied by an increase of
protein-bound w-OH-FA at the affected skin, whereas the amount
of unhydroxylated fatty acids remained essentially unchanged. We
were able to con®rm this observation by a metabolic labeling study,
in which the total amount of newly synthesized protein-bound
lipids was remarkably reduced in atopic affected regions and the
w-OH-Cer and w-OH-FA were more affected than the un-
hydroxylated fatty acids (not shown).
In conclusion, not only the affected skin but also the nonlesional
skin revealed a marked reduction of protein-bound w-OH-Cer
indicating that the atopic predisposition affects the skin at a
molecular level even without acute in¯ammatory manifestations.
The w-hydroxylated protein-bound lipids seem to be attached to
the structural proteins of the corneocyte exclusively by their
w-hydroxy group (Doering et al, 1999a, b; Stewart and Downing,
2001). They act as a bridge between protein-enriched corneocytes
and the multilamellar lipid layers, anchoring the corneocytes into
the lipid matrix. The partial de®ciency of the protein-bound
w-OH-Cer in the lesional atopic skin suggests an important role of
these hydrophobic and uncharged lipoprotein corneocyte surfaces
for the epidermal barrier function. Presumably, these lipoproteins
serve as a scaffold for the establishment of the intercellular lipid
sheets parallel to the surface of the corneocyte (Ponec et al, 2000), a
function that cannot be accomplished by the anionic w-OH-FA as
they would generate a charged corneocyte surface. It remains
unclear to what extent the composition of the protein-bound lipids
could in¯uence the lipid organization of the intercellular unbound
barrier lipids (Bouwstra et al, 1999; Schreiner et al, 2000).
The increase of protein-bound w-OH-FA at the expense of the
bound w-OH-Cer could be caused by the action of an unknown
ceramidase, e.g. of exogenous origin (Okino et al, 1998). The rate
of colonization with ceramidase-secreting bacteria increases with
the severity of skin lesions of AD patients (Ohnishi et al, 1999). The
bacterial ¯ora from AD patients secretes signi®cantly more
ceramidase than the bacterial ¯ora from healthy subjects, whereas
the secretions of bacterial sphingomyelinases in AD patients and
healthy controls are comparable (Ohnishi et al, 1999). The action of
an endogenous human ceramidase in cooperation with sphingolipid
activator-proteins C and D cannot be excluded, however (Schuette
et al, 2001).
The content of covalently bound unhydroxylated fatty acids,
which were released by mild alkaline hydrolysis, remained
unchanged in affected skin areas. Their origin and the nature of
their linkage to corneocyte proteins is still unclear, even though
they were already described 15 y ago (Wertz and Downing, 1986).
Describing the abnormalities in AD, we have to consider the
severity of the disease. For patients with completely healed AD
(symptom-free for more than 5 y), it was reported that the
transepidermal water loss and the water content of the stratum
corneum do not differ from healthy controls (Matsumoto et al,
2000). On the other hand, in patients with acute AD, even the skin
that has no visible lesions seems to be altered (Seidenari and Giusti,
1995). All data presented here were obtained from skin of acute and
severely affected AD subjects. Less affected subjects may have
barrier lipid contents anywhere in between those of severely
affected subjects and healthy controls.
Lesional atopic skin is also characterized by changes of the free
extractable epidermal barrier lipids, but systematic data on FFA,
even on the VLCFA, are rare. We analyzed FFA in lesional and
nonlesional epidermis of AD subjects and compared them to
healthy controls. The total amount of FFA seemed to be
unchanged in the investigated skin samples, but the amount of
free VLCFA, with more than 24 carbon atoms, was remarkably
reduced in the affected as well as the nonlesional atopic skin
compared to healthy controls. The content of the common fatty
acids, e.g., palmitic acid and stearic acid, remained normal.
Fatty acids are essential for the epidermal permeability barrier
function. The partial reduction of their biosynthesis by application
of 5-tetradecycloxy-2-furancarboxylic acid, an inhibitor of acetyl
coenzyme A carboxylase, to hairless mice skin results in an
Figure 2. Free epidermal VLCFA of subjects with AD. Epidermis
was prepared as described in Materials and Methods. Fatty acids were
extracted from epidermis (2 mg dry weight) and esteri®ed with
diazomethane. The methyl esters were separated by capillary gas
chromatography as described in Materials and Methods. The predominant
VLCFA (C26 : 0, C28 : 0, C30 : 0) are shown. Panel A, lesional area;
panel B, nonlesional area of the same atopic subject. The annotated peaks
(number of carbon atoms: number of double bonds) were identi®ed by
relative retention times of authentic standards.
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impairment in barrier homeostasis (Mao-Qiang et al, 1993). The
suitability of fatty acids for barrier function depends mostly on their
chain length and their state of saturation in order to build highly
organized intercellular membrane structures (Small, 1984). Very
long chain saturated fatty acids are highly hydrophobic and have a
higher ability to prevent water loss in the skin than short chain fatty
acids. Saturated fatty acids are also more resistant to oxidation than
unsaturated fatty acids and are able to build a highly ordered
crystalline state at skin temperature (HoÈltje et al, 2001). Studies on
long chain ceramides and long chain FFA suggest that these lipids
Table II. Biosynthesis of free glucosylceramides and ceramides in epidermis prepared from skin biopsiesa
Lesional area of atopic subjects (n = 2) Healthy subjects (n = 2)
Incorporated radioactivity in total
glucosylceramide-fractionb
(18 mg wet weight epidermis/24 h)
3100 (6 600) cpm 13 600 (6 1800) cpm
Incorporated radioactivity in total
ceramide fractionc
(18 mg wet weight epidermis/24 h)
2400 (6 700) cpm
(= 100%)
5200 (6 600) cpm
(= 100%)
Radioactivity incorporated in percent of total ceramide fraction
Cer EOS (Cer 1) 9% (6 4) 11% (6 0.5)
Cer NS (Cer 2, long N-acyl fatty acid)d 36% (6 6) 37% (6 3)
Cer NS (Cer 2, short N-acyl fatty acid)e 29% (6 2) 19% (6 0.5)
Cer NP (Cer 3) 9% (6 1) 13% (6 1)
Cer EOH (Cer 4) 5% (6 0.5) 8% (6 2)
Cer AS (Cer 5) 5% (6 1) 5% (6 0.5)
Cer AP, AH (Cer 6, 7) 7% (6 2) 7% (6 2)
aEpidermis was prepared and incubated for 24 h with [14C]-serine as described in Materials and Methods. Radioactivity incorporated into the free extractable lipids was
quanti®ed by liquid scintillation counting; the lipid composition was analyzed by TLC (Fig 3) and visualized by phospho-imager analysis (abbreviations of free epidermal
ceramides according to Motta et al, 1993; Robson et al, 1994). [14C]-Serine incorporation into glucosylceramides and ceramide species is given as the mean (6SEM).
bThe total glucosylceramide formation in 24 h per mg wet weight epidermis can be calculated to be 1.45 pmol in the lesional area of a subject with AD and 6.4 pmol in
healthy control skin.
cThe total ceramide formation was about 1.1 pmol (in 24 h per mg wet weight epidermis) at the lesional site of an atopic subject and about 2.4 pmol (in 24 h per mg
wet weight epidermis) for the healthy control.
dLong N-acyl fatty acids are predominantly C24 (Wertz et al, 1985).
eShort N-acyl fatty acids are predominantly C16 and C18.
Figure 3. Biosynthesis of free epidermal
glucosylceramides and ceramides of healthy
individuals and in lesional skin of AD
subjects. Epidermis (18 mg wet weight) from
skin biopsies was incubated for 24 h with 3-[14C]-
serine. The free extractable glucosylceramides and
ceramides were separated by TLC and the
radioactive bands were visualized by phospho-
imager analysis as described in Materials and
Methods (abbreviations of free epidermal ceramides
according to Motta et al, 1993; Robson et al,
1994). Short N-acyl bound fatty acids are
predominantly C16 and C18; long N-acyl bound
fatty acids are predominantly C24. Non-lesional
skin areas of the analyzed atopic subjects were not
available.
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form crystalline (gel) domains that are impermeable to water
(Forslind, 1994). Such homogeneous arrangements seem to be
essential for an ef®cient barrier function as this lateral lipid
organization seems to be altered in several skin diseases (Pilgram
et al, 2001).
Furthermore, differential scanning calorimetry and X-ray analysis
revealed that the ¯exibility of saturated hydrocarbon chains could
be needed in the lipid barrier sheets to balance the disordering
effect of cholesterol (Mizushima et al, 1995). As tight acyl chain
packing is a key feature of lipid sheet organization in the stratum
corneum, the decrease of VLCFA could lead to a destabilization of
the multilamellar intercellular lipid layers in lesional areas of AD
epidermis, especially because the amount of cholesterol is increased
in atopic affected skin regions (Di Nardo et al, 1998).
Barrier disturbances induced by acetone or tape stripping in
hairless mice, resulting in the loss of water and body heat, are
correlated with hyperproliferation of the keratinocytes as indicated
by an increased DNA synthesis. The activity levels of 3-hydroxy-3-
methylglutaryl-coenzyme A reductase and serine-palmitoyl trans-
ferase, key enzymes for the biosynthesis of cholesterol and
sphingolipids, are elevated (Proksch et al, 1993). Beside this, the
mRNA levels of fatty acid synthase and other enzymes required for
barrier lipid syntheses are coordinately upregulated as a metabolic
response after barrier disruption (Harris et al, 1997). Furthermore,
local in¯ammation results in a remarkably increased expression of
fatty acid synthase in the lower stratum spinosum and stratum basale
of AD subjects (Uchiyama et al, 2000). Though these changes
would suggest an increased synthesis of sphingolipids and fatty acids
in combination with barrier repair, the content and the biosynthesis
of the crucial free VLCFA, as well as the very long acyl chain and
phytosphingosine containing ceramides and glucosylceramides, are
dramatically reduced in lesional atopic epidermis. Our data suggest
that the keratinocytes in AD lesional epidermis suffer from a
de®ciency of very long acyl chain biosynthesis, which is known to
require unusually high amounts of metabolic energy. These
keratinocytes may have insuf®cient metabolic energy levels,
especially under the stress situation of acute in¯ammation and
chronic barrier disruption.
Changes in epidermal ceramide content could also be due to
altered glucosylceramide and sphingomyelin metabolism (Holleran
et al, 1993; Jensen et al, 1999; Schmuth et al, 2000). Most of the
glucosylceramides are degraded by the b-glucocerebrosidase to the
corresponding ceramides during their secretion into the inter-
cellular space at the stratum granulosum±stratum corneum interface
(Holleran et al, 1994). It has recently been described that even
epidermal sphingomyelins are precursors of selected barrier
ceramides (Uchida et al, 2000). The activities of the two catabolic
enzymes, b-glucocerebrosidase (Jin et al, 1994) and sphingomye-
linase (Kusuda et al, 1998), were reported to be essentially
unchanged in the epidermis of AD patients. The increased activity
of a sphingomyelin deacylase in AD skin could also trigger a
de®ciency of ceramides, however, and disrupt the barrier homeo-
stasis (Murata et al, 1996; Hara et al, 2000). The origin of this
enzyme, bacterial or endogenous, still remains to be settled.
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